California medical device company RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) system has shown potential for improved ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The Phase I ADC trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing ...

The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Medidata has announced the extension of its partnership of 13 years with Tigermed to enhance clinical trial processes.

Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...

Rigel has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to ...

GlobalData epidemiologists forecast a rise in dementia cases in the US from 2.97 million in 2024 to 4.06 million by 2033.

The study found that the number of advanced therapy Phase I trials in the UK nearly doubled since the same time in 2023.